Frustration builds at Mylan over EpiPen woes

Mylan (Nasdaq: MYL) is pressuring manufacturing partner Pfizer (NYSE: PFE) to take a more active role in solving the ongoing shortage of EpiPen (epinephrine autoinjector) devices as the companies prepare to face heightened demand for the emergency anaphylaxis treatment.

Production of the devices, which takes place at Pfizer's manufacturing facility in Missouri, slowed in late 2017 after the facility receieved sharp criticism from US Food and Drug Administration inspectors on quality control grounds. The delays have led to around 400 patients being unable to access the potentially life-saving drug.

The delays are likely to get worse if not resolved quickly, as the return of the school year approaches and young people with severe allergies head back to school.